Asia
CONBA Receives China Clinical Trial Approval for Heart-Clearing Traditional Drug
Zhejiang CONBA Pharmaceutical (SHA:600572) received clinical trial approval from China's National Medical Products Administration for its heart-clearing traditional Chinese drug, according to a Saturday filing with the Shanghai bourse.The drug is indicated for heart failure with preserved ejection fraction.Total sales of traditional Chinese drugs for cardiovascular conditions reached 49.2 billion yuan in 2025, according to market data cited in the filing.
SHA:600572
